Kymera Therapeutics, Inc. — Earnings Quality Grade F
KYMR · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
AR growth -100.0% vs revenue growth -40.1%
Revenue -16.7%, CFFO -19.7%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -88.7% vs revenue -16.7%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF is negative ($-0.2B)
Accruals ratio = -4.5%. Low accruals
Cash $0.8B covers debt $0.1B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -933.9x (<2x). Financial stress
Other assets grew 92.6% vs revenue -16.7%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor KYMR continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25